Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096290 | 0.73 | CYP3A4 (0.35) | CYP3A4ABCG2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL11789243 | 0.73 | MEN1 (0.37) | CYP3A4ABCG2HTR3EHTR3BHTR3A | |
| SCHEMBL717364 | 0.73 | CYP3A4 (0.35) | CYP3A4ABCG2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL789550 | 0.73 | CYP3A4 (0.35) | CYP3A4ABCG2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL7047825 | 0.73 | CYP3A4 (0.35) | CYP3A4ABCG2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL1742802 | 0.69 | CYP3A4 (0.44) | CYP3A4ABCG2HTR3EHTR3BHTR3A | |
| SCHEMBL4403183 | 0.68 | LMNA (0.41) | CYP3A4ALDH1A1MAPK1ATM | |
| SCHEMBL8472910 | 0.68 | ALDH1A1 (0.33) | CYP3A4ABCG2ALDH1A1TAAR1 | |
| SCHEMBL20564350 | 0.68 | HSD17B10 (0.33) | CYP3A4ABCG2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL910508 | 0.66 | MAPT (0.47) | CYP3A4ALDH1A1TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021183702-A1 | GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-09-16 | — | — | WO | claimed |
| WO-2021183702-A1 | GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-09-16 | — | — | WO | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2038041-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | Myriad Genetics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-2026882-A2 | ASSOCIATION OF A TENSOR AGENT OR DEVICE AND A SACCHARIDE COMPOUND | L'Oréal (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007128939-A2 | ASSOCIATION OF A TENSOR AGENT OR DEVICE AND A SACCHARIDE COMPOUND | L'OREAL (FR) | 2007-11-15 | — | — | WO | disclosed |
| EP-1792642-A2 | Cosmetic composition comprising a statistic polymer with an ethylenic main chain | L'OREAL (FR) | 2007-06-06 | — | — | EP | disclosed |
| EP-1776946-A2 | Cosmetic composition containing a statistical vinyl polymer with linear main chain | L'OREAL (FR) | 2007-04-25 | — | — | EP | disclosed |
| EP-0676451-B1 | Aqueous dispersions of resins, their use in cosmetics and cosmetic compositions obtained therefrom | OREAL (FR) | 1997-02-05 | — | — | EP | disclosed |
| EP-0676451-A1 | Aqueous dispersions of resins, their use in cosmetics and cosmetic compositions obtained therefrom | L'OREAL (FR) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | CYP3A4 2120/4885ABCG2 67/4885HTR3E 2865/4885 |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | CYP3A4 2120/4885ABCG2 67/4885HTR3E 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.